Praxis Precision Medicines, Inc. appointed Jeffrey B. Kindler and Stuart Arbuckle to its board of directors a Class II director, effective January 8, 2026. Jeffrey B. Kindler brings exceptional experience in enterprise leadership, capital allocation, and strategic transaction execution across the biopharmaceutical industry. As former chairman and chief executive officer of Pfizer, Mr. Kindler led large-scale R&D and operating model transformations while overseeing major acquisitions and partnerships that reshaped the company?s portfolio and long-term growth trajectory.
He is widely recognized for his expertise in public-company leadership and navigating high-stakes strategic decisions. Mr. Kindler currently serves as a director and advisor to multiple healthcare and life sciences companies. Stuart Arbuckle is a highly accomplished executive with deep experience leading global commercial success at biopharmaceutical organizations.
He spent 13 years at Vertex Pharmaceuticals, most recently serving as Executive Vice President and Chief Operating Officer, where he oversaw, among many areas, Vertex?s global commercial, human resources and program, and portfolio management and played a pivotal role in the company?s global growth and scale. Prior to Vertex, Mr. Arbuckle held multiple commercial leadership roles at Amgen and GSK. He currently serves on the boards of directors of Rhythm Pharmaceuticals and Alnylam Pharmaceuticals.
Megan Sniecinski, currently Chief Business Officer, has been promoted to Chief Operating Officer, effective January 1, 2026. In this role, Ms. Sniecinski will be accountable for operationalizing the company?s growth strategy, overseeing enterprise execution, program strategy and operations, and corporate development. Ms. Sniecinski, age 45, served as Chief Business Officer of the Company from December 2021 through December 2025.
Prior to joining the Company, she served as chief business officer at BioCryst Pharmaceuticals from 2019 to 2021, overseeing corporate development, global medical affairs, program management and global supply chain. From 2017 to 2019, she was senior vice president of business operations and program management at PTC Therapeutics, where she led established and grew the program management function and led business development during the company?s transition toward becoming fully integrated, and commercial stage organization. Before joining PTC, Ms. Sniecinski spent more than a decade at Merck serving in a diverse set of operational and strategic roles supporting their manufacturing operations, commercial and G&A divisions, with increasing responsibility, culminating as director of business development and strategic partnerships at Merck Vaccines.
Ms. Sniecinski received a B.S. in chemical engineering from the University of Virginia and an MBA from the Wharton School of the University of Pennsylvania. Dr. Steven Petrou, currently Chief Scientific Officer, has been promoted to President of Research & Development, reflecting the company?s evolution into a late-stage organization with multiple programs advancing toward registration and commercialization. Dr. Petrou is a globally recognized leader in ion channel disease biology and precision medicine and has been a principal architect of Praxis?s scientific foundation, translational engine, and development strategy.
As a co-founder of Praxis and as the company has evolved, Dr. Petrou has led the integration of discovery, preclinical, translational, and clinical functions to build a highly differentiated CNS portfolio addressing severe neurological disorders with significant unmet need. In this expanded role, Dr. Petrou will continue to oversee the full R&D continuum to maximize the probability of technical and commercial success across the company?s pipeline. Effective February 6, 2026, upon the recommendations of the Nominating and Corporate Governance Committee of the Board, the Board appointed Mr. Kindler as a member of the Audit Committee of the Board and the Nominating Committee and Mr. Arbuckle as a member of the Compensation Committee of the Board and the Science and Technology Committee of the Board.
